Condition: Chronic Pain · Opioid Use Disorder · Sponsor: Yale University
This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of Cannabidiol (CBD) on measures of pain and opioid craving in outpatients with opioid use disorder (OUD) receiving medication-assisted treatment with methadone or buprenorphine. With a duration of approximately 4 weeks, participants will come to the testing site for a total of five times: one initial screening session, and four experimental sessions where study medication, CBD, will be administered, separated by at least 72 hours to limit carryover effects.
This description comes directly from the study's public registry record.
Joao De Aquino, M.D. · 203-932-5711 · joao.deaquinolima@yale.edu
Julia Meyerovich, M.S. · 203-932-5711 · julia.meyerovich@yale.edu
Always discuss trial participation with your own doctor first.
| Department of Veterans Affairs Hospital | West Haven, Connecticut, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04587791